



Miami Cancer  
Institute

BAPTIST HEALTH SOUTH FLORIDA

# Front-Line Treatment Patterns in Metastatic Castrate-Sensitive Prostate Cancer, The Florida Experience


Isabel C. Houltzet, PharmD, BCPS, BCOP; Irene Arias, PharmD, MS, BCOP; Jorge J. Garcia, PharmD, MS, MHA, MBA, FACHE;  
Elizabeth Bec, PharmD Candidate; Manmeet Ahluwalia, MD, MBA; Winston Tan MD  
Miami Cancer Institute, Baptist Health South Florida; Pfizer Oncology Medical Affairs; Florida Society of Clinical Oncology



## Introduction

- Treatment of metastatic castration sensitive prostate cancer (mCSPC) has evolved in recent years in that, while androgen deprivation therapy (ADT) remains the backbone of treatment, the addition of concurrent novel hormone therapies (NHT), such as abiraterone, or apalutamide, or enzalutamide, or in patients with high volume disease, the chemotherapy agent docetaxel, has become the new standard of care.<sup>1</sup>
- Landmark trials have demonstrated improved overall survival that ranged from 53.3 to 57.6 months and a three-year survival greater than 80% for these patients.<sup>2-6</sup>
- The National Comprehensive Cancer Network (NCCN) guidelines have assigned a level 1 recommendation for combination treatment options in patients with mCSPC, including ADT along with an NHT or docetaxel.
- The Commission on Cancer (CoC) and the Quality Oncology Practice Initiative (QOPI) describe standards for cancer care, including utilizing data for continuous quality improvement and tracking adherence to nationally recognized guidelines to drive treatment selection.<sup>7,8</sup>
- In Florida, the utilization of NHT-based treatment has been up trending in the past three years; however, LHRH monotherapy remains the dominant modality as first-line treatment in newly diagnosed mCSPC patients.
- With multiple treatment options available for mCSPC, prescribing patterns can vary widely. The Florida Society of Clinical Oncology (FLASCO) is committed to being a leading organization promoting quality through care standardization.

### mCSPC Treatment Evolution



## Objectives

- Present data from medical and pharmacy claims to understand current state as it relates to treatment patterns, as well as potential barriers in the adoption of standard of care (SOC) treatment for mCSPC patients at various institutions
- Evaluate real-world thoughts and opinions via a multidisciplinary approach that includes medical oncology, radiation oncology, and urology providers in the treatment of patients with mCSPC to help identify barriers to utilizing SOC treatments in the state of Florida
- Implement an action plan in the state of Florida that will help bridge the gap in treatment incongruences between providers managing patients with mCSPC

## Methods

- Physician champions identified at various healthcare organizations within the state of Florida
- FLASCO-developed pre-survey distributed to understand baseline influences and barriers in prescribing treatments for mCSPC
- Retrospective, descriptive analyses on treatment patterns presented and discussed with leaders
- Unbranded education to be provided to each of the champion sites to include information on current approaches, as well as guideline recommendations for the treatment of men with advanced prostate cancer
- Analyze pre-survey feedback to identify barrier and opportunities for improvement
- Implement standards for optimizing patient outcomes and address barriers identified along the process
- Obtain feedback regarding implementation via a post-survey developed by FLASCO to assess its impact

**The Florida Society of Clinical Oncology**

**PROSTATE CANCER EVIDENCE BASED GUIDELINE ADOPTION**

Within the state of FL, both medical oncology and urology are significantly behind the national average when it comes to adoption of evidence based clinical guidelines for mCSPC. Our goal is to reduce unwarranted gaps that exist between clinical evidence and clinical practice within the state of Florida.

**Your Practice Name:**

**Your Specialty:** *(Please check answer in empty box provided below)*

<input type="checkbox"/> Urology	<input type="checkbox"/> Medical Oncology	<input type="checkbox"/> Radiation Oncology
----------------------------------	---	---

**Your Credentials:** *(Please check answer in empty box provided below)*

<input type="checkbox"/> MD	<input type="checkbox"/> APRN	<input type="checkbox"/> PA	<input type="checkbox"/> PhD	<input type="checkbox"/> PharmD	<input type="checkbox"/> RN	<input type="checkbox"/> Other
-----------------------------	-------------------------------	-----------------------------	------------------------------	---------------------------------	-----------------------------	--------------------------------

*(Please write response in boxes below)*

Age	
Number of years in practice	
Gender	
Do you see patients with biochemical recurrence of prostate cancer?	

*(Please place an X for your selection in the boxes below)*

Confidence in Prostate Cancer Treatment - Please rate yourself:	Poor	Fair	Good	Very Good	Excellent
Staging					
Treatment Options					
Biochemical Recurrence					
Metastatic Castrate Sensitive					
Metastatic Castrate Resistant					

**When do you treat with 2<sup>nd</sup> generation antiandrogen agents or chemotherapy in the first line setting for mCSPC**  
*(Please write response below)*

- Why?

**When do you NOT treat with 2<sup>nd</sup> generation antiandrogen agents or chemotherapy in the first line setting for mCSPC**  
*(Please write response below)*

- Why?

**What are the factors that affect your prescribing/practice?**  
*(Please write response below)*



**What barriers are you facing as it relates to following treatment guidelines (i.e. payor/financial/overall health)?**  
*(Please write response below)*

**How do you think we can improve patient care in your practice and why?**  
*(Please write response below)*

**THANK YOU FOR YOUR PARTICIPATION IN THIS SURVEY!**

WEBSITE: [WWW.FLASCO.ORG](http://WWW.FLASCO.ORG) | PHONE: 813 677 0246 | EMAIL: [INFO@FLASCO.ORG](mailto:INFO@FLASCO.ORG)

### mCSPC Treatment Utilization by Year



## References

- Hahn, A. W., et al. (2018). Metastatic castration-sensitive prostate cancer: Optimizing patient selection and treatment. *American Society of Clinical Oncology Educational Book*, (38), 363-371. doi:10.1200/edbk.200967
- Sweeney CJ, Chen Y-H, Carducci M, et al. Chemo hormonal therapy in metastatic hormone-sensitive prostate cancer (CHAARTED). *N Engl J Med* 2015;373:737-746
- James, N. D., et al. (2016). Addition of Docetaxel, zoledronic acid, or both TO First-line Long-Term hormone therapy in prostate cancer (STAMPEDE): Survival results from an Adaptive, multiarm, multistage, platform randomised controlled trial. *The Lancet*, 387(10024), 1163-1177. doi:10.1016/s0140-6736(15)01037-5
- Fizazi K, Tran N, Fein L, et al. LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. *N Engl J Med*. 2017;377:352-360.
- Davis ID, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. (ENZAMETE) *N Engl J Med*. (2019) 381:121-31. doi:10.1056/nejmoa1903835
- Chi KN, et al. Apalutamide for metastatic, castration-sensitive prostate cancer.(TITAN) *N Engl J Med*. (2019) 381:13-24.
- American College of Surgeons Commission on Cancer: Cancer Program Standards: Ensuring Patient-Centered Care, 2016 edition. Available at <https://facs.org/quality-programs/cancer/coc/standards>. Accessed March 17, 2021
- McNiff K, Bonelli K, Jacobson J. American Society of Clinical Oncology/ Quality Oncology Practice Initiative Certification Program: Overview, Measure Scoring Methodology, and Site Assessment Standards. *J Oncol Practice* 5(6):2009

## Disclosures

- Database evaluation support provided by Pfizer Oncology-Medical Affairs-Health Data Analytics Specialist

## Potential Impact

- Through this state-wide initiative, we hope to open up the dialogue across provider specialties to understand treatment patterns and barriers that exist in prescribing SOC regimens for the treatment of mCSPC
- With the collaboration of physician champions at various institutions throughout the state of Florida, FLASCO aims to help overcome potential barriers and homogenize treatment selection in patients diagnosed with mCSPC
- While keeping our patients' health at the forefront of our investigation, we anticipate an increase in the use of SOC treatments throughout all disciplines of medicine that are involved in the care of mCSPC patients, and aspire to set a precedent with the goal to optimize care nationally